BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

Executive Summary

• BioNxt Solutions Inc. completed a Track One priority patent filing with the USPTO for its sublingual thin‑film cladribine formulation (BNT23001) targeting multiple sclerosis.
• The fast‑track status accelerates U.S. protection and strengthens the company’s IP position ahead of pivotal bioequivalence studies and partnership discussions.
• Favorable communications have been received from the European Patent Office and Eurasian Patent Office, with nationalization efforts underway in key global markets.

Key Details

• Track One filing: Completed for BNT23001 (sublingual thin‑film cladribine) under USPTO’s accelerated program; office action expected within 60–90 days, final disposition within 9–12 months.
• Scope of filing: Covers sublingual formulations for multiple sclerosis and other neurological autoimmune diseases such as myasthenia gravis and lupus nephritis.
• Global patent nationalization: Ongoing in the EU, U.S., Canada, Australia, Eurasia, New Zealand, and Japan; European and Eurasian offices have issued favorable communications indicating intent to grant.
• Validation points: Novelty, inventive step, and industrial applicability accepted; only formal non‑material adaptations required for national filings.
• Strategic impact: Enhances IP portfolio ahead of upcoming bioequivalence studies and commercial partnering negotiations, potentially facilitating licensing or joint‑development agreements.

Notable Quotes

(No direct quotes were provided in the release.)